Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Trump Says Anthropic No Longer Seen as National Security Threat 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
DUBLIN, Ireland, Feb. 01, 2016 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in two upcoming meetings:
- BIO CEO & Investor Conference on February 8, 2016 in New York, NY. Prothena President and Chief Executive Officer Dale B. Schenk, PhD will present an update on the company’s business at 10:00 AM ET and participate in a fireside chat at 1:30 PM ET.
- Leerink Partners 5th Annual Global Healthcare Conference on February 11, 2016 at 8:55 AM ET in New York, NY.
A live webcast of the presentations from both conferences can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, replays of the webcasts will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).
For more information, please visit the company's web site at www.prothena.com.
Contacts Investors: Tran Nguyen, CFO 650-837-8535, [email protected] Media: Ellen Rose 650-922-2405, [email protected]
